Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Younger Men Face Higher Mortality Risk in Advanced Prostate Cancer: An Analysis of IRONMAN Registry Data
/in Observational/by MaxYounger age is generally associated with better health and longer life expectancy. However, new findings from the international IRONMAN registry suggest a different pattern in advanced prostate cancer: men diagnosed at age 55 or younger may have worse survival outcomes than those diagnosed at middle or older ages. The analysis included 4,332 patients from 15 […]
UPDATE: ABBV-969 Shows Strong Molecular Responses in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNew biomarker data provide additional evidence of the preliminary activity of ABBV-969, an investigational antibody-drug conjugate (ADC) designed to target both PSMA and STEAP1 in metastatic castration-resistant prostate cancer (mCRPC). The findings come from the ongoing Phase 1 study, involving 49 heavily pretreated patients who had received a median of five previous treatment lines. Most […]
UPDATE: ²²⁵Ac-LNC1011 Achieves 86.7% PSA50 Response in Early mCRPC Study
/in Clinical Trial, Metastatic, Phase 1/by MaxNew results presented at EANM 2026 provide further evidence of the preliminary clinical activity of ²²⁵Ac-LNC1011, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). We have previously discussed this therapy in this post. Following the initial results, the new prospective study includes 15 patients previously treated with androgen receptor pathway inhibitors […]
ZZ-FIRST Trial: Adding Talazoparib to Enzalutamide Shows No Clear Additional Benefit in Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxA randomised phase 2 trial published in Nature Medicine has investigated whether adding the PARP inhibitor talazoparib to enzalutamide and androgen deprivation therapy (ADT) can improve outcomes in men with high-volume metastatic hormone-sensitive prostate cancer (mHSPC), regardless of their homologous recombination repair (HRR) mutation status. The study, known as ZZ-FIRST enrolled 54 patients across eight […]
New PSMA Radiohybrid Combines PET Imaging With Alpha Therapy
/in Preclinical Research/by MaxA new preclinical study published in the Journal of Nuclear Medicine has investigated rhPSMA-10.1, a radiohybrid compound designed to combine PET imaging with targeted alpha therapy for prostate cancer. The approach uses two closely related versions of the same PSMA-targeting molecule: ¹⁸F/La-rhPSMA-10.1 for PET imaging and ²²⁵Ac-rhPSMA-10.1 for treatment. Their similar chemical properties could allow […]
Phase 2 Trial Tests Tinengotinib With Darolutamide or Enzalutamide in Hormone-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxA newly registered phase 2 clinical trial will investigate whether combining tinengotinib (TT-00420) with darolutamide or enzalutamide can improve disease control in men with metastatic castration-resistant prostate cancer (mCRPC). Tinengotinib is an oral multikinase inhibitor targeting several pathways involved in cancer growth and survival, including FGFR, JAK, VEGFR and Aurora kinases. Unlike darolutamide and enzalutamide, […]
Phase 1 Trial Investigates MAO-A Inhibition With ITR-251 to Overcome Prostate Cancer Resistance
/in Clinical Trial, Metastatic, Phase 1/by MaxA new Phase 1 clinical trial will investigate ITR-251, an experimental inhibitor of monoamine oxidase A (MAO-A), as a potential treatment for advanced solid tumours and metastatic castration-resistant prostate cancer (mCRPC). What makes this investigation unusual is its molecular target. MAO-A is an enzyme best known for breaking down neurotransmitters and other monoamines. However, research […]
Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA newly registered phase 1/2 clinical trial will investigate whether combining two immunotherapies with complementary mechanisms can improve treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The study, known as JET-201, plans to enrol 107 patients in the United States and South Korea. The combination brings together pasritamig (JNJ-78278343), a bispecific antibody designed […]